152 related articles for article (PubMed ID: 17696754)
21. Enhanced induction of anti-tumor CTLs in vitro by a lentivirus-transduced dendritic cell vaccine expressing secondary lymphoid tissue chemokine and mucin 1.
Wang B; Zhu Y; Zhang JJ; Chen Z; Liang WB; Xu ZK
Asian Pac J Cancer Prev; 2011; 12(11):2811-7. PubMed ID: 22393946
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic aspects of polymorphic epithelial mucin in adenocarcinoma.
Miles DW; Taylor-Papadimitriou J
Pharmacol Ther; 1999 Apr; 82(1):97-106. PubMed ID: 10341360
[TBL] [Abstract][Full Text] [Related]
23. MUC1 plays an essential role in tumor immunity of colorectal cancer stem cell vaccine.
Guo M; Luo B; Pan M; Li M; Zhao F; Dou J
Int Immunopharmacol; 2020 Aug; 85():106631. PubMed ID: 32470879
[TBL] [Abstract][Full Text] [Related]
24. A totally synthetic, self-assembling, adjuvant-free MUC1 glycopeptide vaccine for cancer therapy.
Huang ZH; Shi L; Ma JW; Sun ZY; Cai H; Chen YX; Zhao YF; Li YM
J Am Chem Soc; 2012 May; 134(21):8730-3. PubMed ID: 22587010
[TBL] [Abstract][Full Text] [Related]
25. Development and preclinical evaluation of a Bacillus Calmette-Guérin-MUC1-based novel breast cancer vaccine.
Chung MA; Luo Y; O'Donnell M; Rodriguez C; Heber W; Sharma S; Chang HR
Cancer Res; 2003 Mar; 63(6):1280-7. PubMed ID: 12649188
[TBL] [Abstract][Full Text] [Related]
26. Strategies for Synthesizing and Enhancing the Immune Response of Cancer Vaccines Based on MUC1 Glycopeptide Antigens.
Yin L; Zhou Y; Hong S; Ding F; Cai H
Chembiochem; 2023 May; 24(10):e202200805. PubMed ID: 36825431
[TBL] [Abstract][Full Text] [Related]
27. A novel Bacillus Calmette-Guérin-based breast cancer vaccine that coexpresses multiple tandem repeats of MUC1 and CD80 breaks the immune tolerance and inhibits MUC1-positive breast cancer growth.
Yuan S; Shi C; Lv Y; Wang T; Wang H; Han W
Cancer Biother Radiopharm; 2009 Oct; 24(5):607-13. PubMed ID: 19877891
[TBL] [Abstract][Full Text] [Related]
28. MUC1-derived glycopeptide libraries with improved MHC anchors are strong antigens and prime mouse T cells for proliferative responses to lysates of human breast cancer tissue.
Gad M; Jensen T; Gagne R; Komba S; Daugaard S; Kroman N; Meldal M; Werdelin O
Eur J Immunol; 2003 Jun; 33(6):1624-32. PubMed ID: 12778480
[TBL] [Abstract][Full Text] [Related]
29. Intradermal vaccination of MUC1 transgenic mice with MUC1/IL-18 plasmid DNA suppresses experimental pulmonary metastases.
Shi FF; Gunn GR; Snyder LA; Goletz TJ
Vaccine; 2007 Apr; 25(17):3338-46. PubMed ID: 17292519
[TBL] [Abstract][Full Text] [Related]
30. Enhanced immunogenicity of multivalent MUC1 glycopeptide antitumour vaccines based on hyperbranched polymers.
Glaffig M; Palitzsch B; Stergiou N; Schüll C; Strassburger D; Schmitt E; Frey H; Kunz H
Org Biomol Chem; 2015 Oct; 13(40):10150-4. PubMed ID: 26299280
[TBL] [Abstract][Full Text] [Related]
31. Potential for novel MUC1 glycopeptide-specific antibody in passive cancer immunotherapy.
Madsen CB; Wandall HH; Pedersen AE
Immunopharmacol Immunotoxicol; 2013 Dec; 35(6):649-52. PubMed ID: 24063621
[TBL] [Abstract][Full Text] [Related]
32. Towards a fully synthetic MUC1-based anticancer vaccine: efficient conjugation of glycopeptides with mono-, di-, and tetravalent lipopeptides using click chemistry.
Cai H; Huang ZH; Shi L; Zhao YF; Kunz H; Li YM
Chemistry; 2011 May; 17(23):6396-406. PubMed ID: 21538615
[TBL] [Abstract][Full Text] [Related]
33. ImMucin: a novel therapeutic vaccine with promiscuous MHC binding for the treatment of MUC1-expressing tumors.
Kovjazin R; Volovitz I; Kundel Y; Rosenbaum E; Medalia G; Horn G; Smorodinsky NI; Brenner B; Carmon L
Vaccine; 2011 Jun; 29(29-30):4676-86. PubMed ID: 21570434
[TBL] [Abstract][Full Text] [Related]
34. Liposomal Antitumor Vaccines Targeting Mucin 1 Elicit a Lipid-Dependent Immunodominant Response.
Du JJ; Zou SY; Chen XZ; Xu WB; Wang CW; Zhang L; Tang YK; Zhou SH; Wang J; Yin XG; Gao XF; Liu Z; Guo J
Chem Asian J; 2019 Jun; 14(12):2116-2121. PubMed ID: 31042017
[TBL] [Abstract][Full Text] [Related]
35. Technology evaluation: TG-1031, Transgene SA.
Doehn C; Jocham D
Curr Opin Mol Ther; 2000 Feb; 2(1):106-11. PubMed ID: 11249647
[TBL] [Abstract][Full Text] [Related]
36. Cancer immunotherapy: phase II clinical studies with TG4010 (MVA-MUC1-IL2).
Acres B
J BUON; 2007 Sep; 12 Suppl 1():S71-5. PubMed ID: 17935281
[TBL] [Abstract][Full Text] [Related]
37. Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer.
Rochlitz C; Figlin R; Squiban P; Salzberg M; Pless M; Herrmann R; Tartour E; Zhao Y; Bizouarne N; Baudin M; Acres B
J Gene Med; 2003 Aug; 5(8):690-9. PubMed ID: 12898638
[TBL] [Abstract][Full Text] [Related]
38. Vaccine against MUC1 antigen expressed in inflammatory bowel disease and cancer lessens colonic inflammation and prevents progression to colitis-associated colon cancer.
Beatty PL; Narayanan S; Gariépy J; Ranganathan S; Finn OJ
Cancer Prev Res (Phila); 2010 Apr; 3(4):438-46. PubMed ID: 20332301
[TBL] [Abstract][Full Text] [Related]
39. Design of a MUC1-based cancer vaccine.
Hanisch FG
Biochem Soc Trans; 2005 Aug; 33(Pt 4):705-8. PubMed ID: 16042579
[TBL] [Abstract][Full Text] [Related]
40. Dendritic cell vaccine immunotherapy of cancer targeting MUC1 mucin.
Kontani K; Taguchi O; Ozaki Y; Hanaoka J; Sawai S; Inoue S; Abe H; Hanasawa K; Fujino S
Int J Mol Med; 2003 Oct; 12(4):493-502. PubMed ID: 12964025
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
